Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 6/20 | 0.52 |
| ▸ | ADH1B | P00325 | 5/20 | 0.52 |
| ▸ | ADH1C | P00326 | 5/20 | 0.52 |
| ▸ | ADH7 | P40394 | 3/20 | 0.52 |
| ▸ | ADH4 | P08319 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508321 | 0.81 | CYP1A2 (0.35) | EPHX1HPGDKMT2AALDH1A1KDM4E | |
| SCHEMBL5508317 | 0.81 | CYP1A2 (0.35) | EPHX1HPGDKMT2AALDH1A1KDM4E | |
| SCHEMBL17592424 | 0.79 | ADH1B (0.42) | ADH1AADH1BADH1CADH7ADH4 | |
| SCHEMBL24044864 | 0.76 | CYP1A2 (0.43) | EPHX1HPGDKMT2AALDH1A1KDM4E | |
| SCHEMBL3613044 | 0.75 | EPHX1 (0.33) | EPHX1HPGDKMT2AALDH1A1KDM4E | |
| SCHEMBL18412494 | 0.74 | ADH1B (0.43) | ADH1AADH1BADH1CADH7ADH4 | |
| SCHEMBL19412553 | 0.74 | CYP1A2 (0.33) | EPHX1HPGDALDH1A1KDM4ECYP1A2 | |
| Propane SCHEMBL28077537 | 0.74 | ADH1B (0.56) | ADH1AADH1BADH1CADH7ADH4 | |
| SCHEMBL24449698 | 0.74 | EPHX1 (0.32) | EPHX1HPGDKMT2AALDH1A1KDM4E | |
| SCHEMBL13744307 | 0.73 | ADH1B (0.42) | ADH1AADH1BADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8338595-B2 | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1765823-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORP (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7563791-B2 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1765823-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121147-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | ADH1A 2524/4885ADH1B 1159/4885ADH1C 1937/4885 |
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | ADH1A 2524/4885ADH1B 1159/4885ADH1C 1937/4885 |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | MKI67, CCNA1, CCNI | ADH1A 3093/4885ADH1B 3761/4885ADH1C 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.